HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RIFM panel

This article was originally published in The Rose Sheet

Executive Summary

Donald Belsito, MD, and Magnus Bruze, MD/PhD, join Research Institute for Fragrance Materials Expert Panel (REXPAN), bringing their experience in contact dermatitis to the group. Belsito, a member of the Cosmetic Ingredient Review Expert Panel, is professor of medicine and director of the Division of Dermatology at the University of Kansas Medical Center and president of the North American Contact Dermatitis Group. Bruze heads the Department of Occupational and Environmental Dermatology at the Malmo University Hospital in Malmo, Sweden and has authored or co-authored about 220 papers, focusing particularly on contact dermatitis and occupational dermatoses. REXPAN is an independent group of dermatologists, pathologists, environmental scientists and toxicologists who advise RIFM on fragrance evaluation...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel